The authors screened 197 registered interventional hypertrophic cardiomyopathy trials, identified 32 landmark trials and extracted race for 13, then compared the Black share of participants with US population, trial site-catchment and echocardiographic disease-prevalence expectations. The pooled Black share was 3.98% (95% CI 2.68 to 5.86) against 16.5% in the adult population, a participation-to-prevalence ratio of 0.24. Site networks reached 63.7% of Black US adults and predicted 26.4% enrolment, while quantitative eligibility thresholds closed only 2.0% of the gap.
Why it is interesting: Enrolment in trials for a condition at least as common in Black as in White Americans fell far below population share, and site geography and eligibility thresholds did not close the gap.